185 related articles for article (PubMed ID: 25479017)
1. Systematic analysis of intracellular trafficking motifs located within the cytoplasmic domain of simian immunodeficiency virus glycoprotein gp41.
Postler TS; Bixby JG; Desrosiers RC; Yuste E
PLoS One; 2014; 9(12):e114753. PubMed ID: 25479017
[TBL] [Abstract][Full Text] [Related]
2. Domains in the simian immunodeficiency virus gp41 cytoplasmic tail required for envelope incorporation into particles.
Celma CC; Manrique JM; Affranchino JL; Hunter E; González SA
Virology; 2001 May; 283(2):253-61. PubMed ID: 11336550
[TBL] [Abstract][Full Text] [Related]
3. Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity.
Yuste E; Reeves JD; Doms RW; Desrosiers RC
J Virol; 2004 Jul; 78(13):6775-85. PubMed ID: 15194752
[TBL] [Abstract][Full Text] [Related]
4. Mutations at the C-terminus of the simian immunodeficiency virus envelope glycoprotein affect gp120-gp41 stability on virions.
Affranchino JL; González SA
Virology; 2006 Mar; 347(1):217-25. PubMed ID: 16380144
[TBL] [Abstract][Full Text] [Related]
5. Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus.
Yuste E; Johnson W; Pavlakis GN; Desrosiers RC
J Virol; 2005 Oct; 79(19):12455-63. PubMed ID: 16160173
[TBL] [Abstract][Full Text] [Related]
6. Truncating the gp41 Cytoplasmic Tail of Simian Immunodeficiency Virus Decreases Sensitivity to Neutralizing Antibodies without Increasing the Envelope Content of Virions.
White E; Wu F; Chertova E; Bess J; Roser JD; Lifson JD; Hirsch VM
J Virol; 2018 Feb; 92(3):. PubMed ID: 29142124
[TBL] [Abstract][Full Text] [Related]
7. Determinants within gp120 and gp41 contribute to CD4 independence of SIV Envs.
Puffer BA; Altamura LA; Pierson TC; Doms RW
Virology; 2004 Sep; 327(1):16-25. PubMed ID: 15327894
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 Envelope Glycoprotein Trafficking through the Endosomal Recycling Compartment Is Required for Particle Incorporation.
Kirschman J; Qi M; Ding L; Hammonds J; Dienger-Stambaugh K; Wang JJ; Lapierre LA; Goldenring JR; Spearman P
J Virol; 2018 Mar; 92(5):. PubMed ID: 29212940
[TBL] [Abstract][Full Text] [Related]
9. Mutations within the putative membrane-spanning domain of the simian immunodeficiency virus transmembrane glycoprotein define the minimal requirements for fusion, incorporation, and infectivity.
West JT; Johnston PB; Dubay SR; Hunter E
J Virol; 2001 Oct; 75(20):9601-12. PubMed ID: 11559792
[TBL] [Abstract][Full Text] [Related]
10. Progressive truncations C terminal to the membrane-spanning domain of simian immunodeficiency virus Env reduce fusogenicity and increase concentration dependence of Env for fusion.
Lin X; Derdeyn CA; Blumenthal R; West J; Hunter E
J Virol; 2003 Jun; 77(12):7067-77. PubMed ID: 12768026
[TBL] [Abstract][Full Text] [Related]
11. Mutagenesis of tyrosine and di-leucine motifs in the HIV-1 envelope cytoplasmic domain results in a loss of Env-mediated fusion and infectivity.
Bhakta SJ; Shang L; Prince JL; Claiborne DT; Hunter E
Retrovirology; 2011 May; 8():37. PubMed ID: 21569545
[TBL] [Abstract][Full Text] [Related]
12. Small variations in the length of the cytoplasmic domain of the simian immunodeficiency virus transmembrane protein drastically affect envelope incorporation and virus entry.
Manrique JM; Celma CC; Affranchino JL; Hunter E; González SA
AIDS Res Hum Retroviruses; 2001 Nov; 17(17):1615-24. PubMed ID: 11779349
[TBL] [Abstract][Full Text] [Related]
13. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.
Chertova E; Bess JW; Crise BJ; Sowder II RC; Schaden TM; Hilburn JM; Hoxie JA; Benveniste RE; Lifson JD; Henderson LE; Arthur LO
J Virol; 2002 Jun; 76(11):5315-25. PubMed ID: 11991960
[TBL] [Abstract][Full Text] [Related]
14. Effect of the cytoplasmic domain of the simian immunodeficiency virus envelope protein on incorporation of heterologous envelope proteins and sensitivity to neutralization.
Vzorov AN; Compans RW
J Virol; 2000 Sep; 74(18):8219-25. PubMed ID: 10954518
[TBL] [Abstract][Full Text] [Related]
15. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions.
Freed EO; Martin MA
J Virol; 1996 Jan; 70(1):341-51. PubMed ID: 8523546
[TBL] [Abstract][Full Text] [Related]
16. Positive and negative modulation of virus infectivity and envelope glycoprotein incorporation into virions by amino acid substitutions at the N terminus of the simian immunodeficiency virus matrix protein.
Manrique JM; Celma CC; Hunter E; Affranchino JL; González SA
J Virol; 2003 Oct; 77(20):10881-8. PubMed ID: 14512538
[TBL] [Abstract][Full Text] [Related]
17. The simian immunodeficiency virus envelope glycoprotein contains multiple signals that regulate its cell surface expression and endocytosis.
Bowers K; Pelchen-Matthews A; Höning S; Vance PJ; Creary L; Haggarty BS; Romano J; Ballensiefen W; Hoxie JA; Marsh M
Traffic; 2000 Aug; 1(8):661-74. PubMed ID: 11208154
[TBL] [Abstract][Full Text] [Related]
18. Impact of natural polymorphism within the gp41 cytoplasmic tail of human immunodeficiency virus type 1 on the intracellular distribution of envelope glycoproteins and viral assembly.
Lambelé M; Labrosse B; Roch E; Moreau A; Verrier B; Barin F; Roingeard P; Mammano F; Brand D
J Virol; 2007 Jan; 81(1):125-40. PubMed ID: 17050592
[TBL] [Abstract][Full Text] [Related]
19. Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells.
Johnston PB; Dubay JW; Hunter E
J Virol; 1993 Jun; 67(6):3077-86. PubMed ID: 8497044
[TBL] [Abstract][Full Text] [Related]
20. Second-site revertants of a simian immunodeficiency virus gp41 mutant defective in envelope glycoprotein incorporation.
Celma CC; Manrique JM; Hunter E; Affranchino JL; González SA
AIDS Res Hum Retroviruses; 2004 Jul; 20(7):733-41. PubMed ID: 15307919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
